Eli Lilly and Company (NYSE:LLY) Shares Bought by Legal & General Group Plc

Legal & General Group Plc increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 7,115,785 shares of the company’s stock after buying an additional 4,214 shares during the period. Eli Lilly and Company accounts for about 1.4% of Legal & General Group Plc’s portfolio, making the stock its 8th largest holding. Legal & General Group Plc owned 0.75% of Eli Lilly and Company worth $6,442,516,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $36,000. Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $909.12 on Friday. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $864.03 billion, a price-to-earnings ratio of 133.89, a PEG ratio of 2.78 and a beta of 0.42. The firm has a 50 day moving average price of $895.70 and a 200-day moving average price of $841.91.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 8,848 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 423,559 shares of company stock valued at $393,136,808 over the last ninety days. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.